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ABSTRACT 
Positron emission tomography (PET) is a useful tool for studying the central nervous system 
(CNS) in living subjects. PET is a non-invasive imaging technique that can visualize 
biochemical process such as receptor-ligand interactions and has been utilized for several 
neurotransmitter systems including the serotoninergic system. Serotonin receptor subtype 1B 
(5-HT1B) is an interesting target to study using PET and two radioligands have been developed 
for this purpose, [11C]AZ10419369 and [11C]P943. Both are labelled with carbon-11 and have 
been used in various PET studies during the last decade. One type of PET study that 
[11C]AZ10419369 and [11C]P943 have been used for is measuring changes in endogenous 5-
HT concentrations in brain. In vitro models show that an agonist could be more sensitive to 
competition from endogenous 5-HT than an antagonist. [11C]AZ10419369 and [11C]P943 were 
both originally presented as antagonists, but [11C]AZ10419369, at least, has been shown to 
have agonist efficacy. Both [11C]AZ10419369 and [11C]P943 are also labelled with shorter-
lived radionuclide carbon-11 (t1/2 = 20.4 min) which limits their use to facilities with a 
cyclotron. A fluorine-18 (t1/2 = 109.7 min) would allow more facilities to conduct PET studies 
on 5-HT1B. 
In this thesis the aim has been to develop a full antagonist and agonist 5-HT1B PET radioligand 
in order to be able to assess whether their intrinsic activity affects their sensitivity towards 
changes in endogenous 5-HT concentrations. From a library of over 3000 compounds, provided 
by AstraZeneca, candidates were selected primarily with respects to their affinity, intrinsic 
activity and lipophilicity. Paper I describes the development of a full antagonist 5-HT1B PET 
radioligand labelled with carbon-11, [11C]AZ10419096, with high specific binding and 
sensitivity to displacement by endogenous 5-HT.  Paper II describes the attempts at developing 
a full agonist 5-HT1B PET radioligand. Neither of the agonists selected were able to enter the 
brain and bind to 5-HT1B receptors in a significant amount. Because of the poor performance 
of the full agonists, a highly agonistic 5-HT1B PET radioligand, [
11C]AZ12175002, which has 
previously been developed and tested in baseline PET measurements, was selected for an initial 
pilot study with a comparison of three PET radioligands with differing intrinsic activity in 
paper III. The study was able to show all three radioligands, [11C]AZ10419369, 
[11C]AZ10419096 and [11C]AZ12175002, are dose-dependently sensitive towards 
fenfluramine induced changes in endogenous 5-HT concentrations. A framework for an 
extended study was established with regards to dose levels and multiples number of PET 
measurements needed at each dose. Paper IV describes the development and initial 
characterization of [18F]AZ10419096, a fluorine-18 labeled version and identical structure of 
[11C]AZ10419096, showing high binding potential and specific binding in blocking PET 
measurement.  
In conclusion, this thesis describes the development of novel carbon-11 labelled PET 
radioligands with differing intrinsic activity and the development of a fluorine-18 labelled PET 
radioligand for future studies of the 5-HT1B receptors in brain. 
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1 INTRODUCTION 
1.1 POSITRON EMISSION TOMOGRAPHY 
Imaging techniques, such as magnetic resonance imaging (MRI) and X-ray, have become an 
important aspect of both biochemical research and medical treatment. While those techniques 
are useful they can only visualize structures and processes on an anatomical scale. Positron 
emission tomography (PET) is a non-invasive imaging technique that can study biological 
processes in living subjects (1,2). PET can be used for studying receptor occupancy, 
metabolism, biodistribution and to identify mechanisms of a disease without any 
pharmacological consequences and has become a useful tool in pharmaceutical research 
and development (3-5). A key aspect of PET imaging is micro-dosing, i.e. a dose well below 
what could be considered pharmacologically active (6). This means PET can be used as an 
early evaluation of new potential pharmaceutical drugs before setting up expensive clinical 
trials (7). PET has been used to study neurotransmitters in brain since the 1980s (8). 
Table 1. Physical data of some of the more commonly used radio-isotopes in PET (2). 
Element O N C F 
Radioisotope 15O 13N 11C 18F 
Half-life (min) 2.04 9.96 20.4 109.7 
Decay product 15N 13C 11B 18O 
Maximal positron energy (MeV) 1.74 1.19 0.97 0.64 
Penetration distance* (mm) 8 5 4 2 
* Maximum distances in water. 
PET utilizes cyclotron generated positron-emitting short-lived isotopes of elements naturally 
occurring in biochemically active molecules, such as carbon, nitrogen, oxygen and fluorine 
(Table 1) (9, 10). A cyclotron is a particle accelerator using a magnetic field to accelerate a 
small particle into a target containing starting material for a nuclear reaction generating 
radioisotopes. These isotopes are incorporated in a biologically active molecule that is 
administered, usually intravenously, to the subject and distributed in the living tissue according 
to the pharmacokinetics of the biomolecule. The short-lived isotopes incorporated in the 
biomolecule decays by emitting a positron that annihilates upon collision with an electron, 
producing two gamma (γ) rays of 511 keV radiating in 180  away from the point of 
annihilation (Figure 1). Depending on the energy of the emitted positron, the positron will 
travel between 1-8 mm before annihilation, lower energy means shorter distance. The distance 
is also dependent on the density of the medium the positron is travelling through. The detection 
of the gamma rays is based on a “coincidence event”, i.e. two γ rays hitting the detectors on 
opposite sides of the subject within a defined time allowing for the determination of the location 
of the annihilation(11). Quantitative image reconstruction can then produce visualization of 
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where in the subject the radioligand has accumulated and generate a tomographic image (12). 
The data can also be represented as time activity curves which displays the accumulation of 
radioactivity in a region over the time of the PET measurement (13). This allows for the 
quantification of the PET data that can be used to describe relative regional distribution of the 
PET radiotracers, binding to targets and blocking or displacement thereof.  
 
Figure 1. Positron decay of a neutron-deficient radionuclide and principle of positron emission tomography (14).  
A positron is emitted from the radionuclide and annihilates upon collision with an electron giving of two 511 
keV γ-rays which can be detected by a PET camera 
 
1.2 CNS PET RADIOLIGAND DEVELOPMENT AND EVALUATION 
Designing PET radioligands for application in the central nervous system (CNS) requires 
considerations of several factors and the resources to perform biological assays to evaluate a 
large number of potential molecules. PET radioligand development has a lot in common with 
pharmaceutical drug development. Early stage development of pharmaceuticals tend to follow 
Lipinski’s rule: 5 or less hydrogen bond donors; less than 10 hydrogen bond acceptors; 
molecular weight below 500; clogP below 5 (15). These rules are considered to be limited to 
oral administration, which is seldom used in PET measurements but still relevant for PET 
radioligands as many of them start of as potential pharmaceuticals. Lately these rules have been 
shown to be only moderately effective predictors even for pharmaceuticals but are still being 
used as initial guidelines (16, 17). A CNS PET radioligand does have a slightly different 
purpose than a pharmaceutical drug. The role of any CNS PET radioligand is to give a clear 
PET image in a micro-dose paradigm from which data can be extracted. For a drug-like 
molecule or pharmaceutical, to be suitable as a CNS PET radioligand it needs to have high 
binding affinity relative to the target receptor concentration (Bmax). Inhibition constant (KI) and 
dissociation constant (KD) are both used to describe affinity but are measured differently. KD 
describes a ratio of free ligand and receptor to receptor-ligand complex at an equilibrium. KI 
describes a ligands ability to competitively inhibit the binding of a second ligand, an 
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endogenous neurotransmitter for example. A target receptor with low Bmax requires a 
radioligand with higher affinity than a radioligand for a target receptor with higher Bmax (18).  
They also need to display high selectivity against binding to other targets, the ability to pass 
the blood brain barrier (BBB) and not produce BBB-crossing radiometabolites (4, 19). The 
PET radioligand needs to bind specifically to the target receptor, a PET radioligand with higher 
non-specific binding will be difficult to use in further studies. The non-specific binding refers 
non-saturable binding such as adherence to fatty tissue in brain.  
1.2.1 Binding potential 
The relationship between KD and Bmax can be seen as a general definition of radioligand binding 
potential (BP) as described in the equation 1.  
BP = Bmax/KD (1) 
BP is further described using volumes of distributions in comparison to different reference 
concentrations (20). Volume of distribution in PET refers to the concentration of a radioligand 
in a specific region divided by the concentration of the radioligand in blood plasma. The 
volume of distribution in the target region (VT) is compared to the volume of distribution in a 
reference compartment (VND) to quantify specifically bound radioligand. Non-displaceable 
binding potential (BPND) is the ratio of specifically bound radioligand to non-displaceable 
radioligand in a reference region with negligible receptor density. fND refers to the fraction of 
radioligand that is non-displaceable in brain as described in equation 2. 
BPND = fNDBavail/KD = (VT−VND)/VND (2) 
Free plasma binding potential (BPF) is the ratio specifically bound radioligand to the 
concentration of unbound radioligand in plasma where fP refers to the fraction of unbound 
radioligand in plasma as described in equation 3. 
BPF = Bavail/KD = (VT−VND)/fP (3) 
Total plasma binding potential (BPP) is the ratio of specifically bound radioligand to combined 
bound and unbound radioligand in plasma as described in equation 4. 
BPP = fPBavail/KD = VT−VND (4) 
All BP values describes the difference between specific binding and non-specific binding and 
are valuable in further studies regarding occupancy and competitive displacement (21). BPF 
and BPP requires arterial blood sampling during the PET measurement in order to quantify fP 
and the specific binding in brain. BPND can be calculated without any blood sampling.  
1.2.2 Occupancy 
This thesis has focused on receptor occupancy, which can be assessed by challenge from 
endogenous ligand or by blocking of the receptor binding site with a competitive unlabeled 
compound (20). In both cases the general idea is to compare the amount of binding sites 
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available to the radioligand with and without competition. The competition can come from an 
unlabeled compound administered prior to the radioligand (pretreatment) or an unlabeled 
compound administered after the radioligand has achieved specific binding in brain 
(displacement). Displacement can only occur if the radioligand binds reversibly to the receptor 
(18). 
1.2.3 Brain uptake  
Lipinski’s rule mentions lipophilicity below 5, measured in clogP, a calculated value. A more 
relevant measurement is logD7.4, a measured relative distribution of a compound between an 
organic phase, octanol, and an aqueous phase at physiological pH, where a more lipophilic 
compound will favor the organic phase. Usually a logD7.4 value of 1-3 is desired. A higher 
logD7.4 value leads higher non-specific binding to the fatty tissue in brain and makes it difficult 
to appreciate receptor-bound radioligand. A higher logD7.4 also increases the adherence to 
protein in the blood and results in a smaller fraction of radioligand free in plasma. Lipophilicity 
also impacts the ability of a radioligand to pass through the BBB via passive diffusion (19). 
Hydrophilic compounds (logD7.4 < 1) have lower ability to passively diffuse through the fatty 
layer of the BBB and tend to stay in the aqueous blood plasma. Polar surface area and formal 
charge at physiological pH affects the ability of a compound to passively diffuse through the 
BBB. If a molecule has a pKa value above or below physiological pH it will be ionized to an 
increasing extent and be more unlikely to pass through the BBB. Brain uptake is also affected 
by efflux transporter protein such as P-glycoprotein (P-gp) or breast cancer resistant protein 
(BCRP) that will actively transport molecules out through the BBB (22, 23). A useful CNS 
PET radioligand cannot be a high-affinity substrate for such efflux pumps. 
1.2.4 Radiometabolism 
Almost all biochemical compounds are susceptible to metabolism in vivo, usually by enzymes 
in the liver (24). Some metabolism can also occur in the brain. Any radio-metabolite that has 
the ability to cross the BBB or is produced in brain will confound the overall quantification of 
a PET measurement. Determination of the amount of the radiometabolites compared to parent 
compound is necessary to identify the nature of the radioactive accumulation in brain (25). 
Blood sampling during a PET measurement allows for determination of the amount of 
radiometabolites as well as the amount of radioligand bound to blood plasma protein (26).  
Radioligand bound to blood plasma protein will not be able to pass through the BBB and bind 
to the intended target in brain (18).  
 
1.3 PET RADIOCHEMISTRY 
Due to the limited half-life of positron emitting radionuclides, the incorporation of the 
radionuclide must be done at a late stage of the total synthesis with the ability to isolate the 
radioligand from any reagents or by-products as well as formulate in an appropriate solution 
for administration (27, 28). To evaluate this process, a few aspects are important: 
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 Radiochemical yield. Radiochemical yield (RCY) is a term used to describe the efficiency of 
a synthesis or process. An accurate descriptions of RCY compares the radioactivity at the start 
of the process or synthesis with the amount of radioactivity of the desired product, decay-
corrected for the time between the start and finish of the synthesis or process.  
Radiochemical purity. Radiochemical purity describes the amount of the radioactivity in a 
sample that originates from one source, expressed as a percentage. Radiochemical purity does 
not take into consideration presence of chemical impurities that do not contribute to the 
radioactivity. 
Molar activity. Molar activity (Am), previously often referred to as specific activity, describes 
the radioactivity in a sample compared to the total amount of labeled and unlabeled compound 
in a sample. Am is not constant but decreases with the half-life of the radionuclide used and is 
given in reference to specific time, such as end of synthesis (EOS) or time of injection (TOI). 
1.3.1 Carbon-11 chemistry 
Cyclotron generated carbon-11 is produced via the nuclear reaction 14N(p,α)11C and depending 
on the gas mixture in the target; either [11C]CH4 (nitrogen/hydrogen) or [
11C]CO2 
(nitrogen/oxygen) is produced. Both carbon species can then be transformed to various useful 
11C-containing reactants (Figure 2). These in turn give rise to an array of product classes e.g., 
[11C]Carbonyl compounds like acids, amides, esters and ketones from [11C]CO2 (29, 30), 
[11C]CO (31, 32), and [11C]HCN (33, 34), [11C]Ureas from [11C]CO2 via isocyantes (35), 
[11C]N-methyl and [11C]O-methyl compounds from [11C]CH3I (36, 37),  and 
11C]CH3OTf(38, 
39) and [11C]thiocarbamates can be synthesized from [11C]CS2 (40).  
Cyclotron produced [11C]CH4 tends to have higher Am than [
11C]CO2 due to less risk of 
contamination from atmosphere. 11C-Carbonylation using [11C]CO and 11C-methylation using 
[11C]CH3OTf are the methods of carbon-11 incorporation used in this thesis. 
 
Figure 2. Possible routes for conversion of cyclotron-produced C-11 into reactive species used in PET 
radiochemistry. 
11C-Carbonylation. Cyclotron generated [11C]CO2 is the starting point for all 
11C-carbonylation 
chemistry utilized in PET chemistry. [11C]CO2 can be used directly in synthesis of 
[11C]carboxylic acids and derivatives like [11C]esters and [11C]amides by reacting the [11C]CO2 
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with an appropriate organometallic compound (Mg, Li) and reducing agent (amine, alcohol or 
water) (41, 42). [carbonyl-11C]Carboxylic acids, esters and amides have also been synthesized 
starting from boronates with CuI catalyst (43).  
Conversion of [11C]CO2 to [
11C]CO can be done through passing the [
11C]CO2 through a heated 
oven containing zinc (400°C) or molybdenum (850°C). The zinc method generally provides 
better conversion than molybdenum but molybdenum has been shown to be more reliable (44, 
45). [11C]CO can also be produced through a two-step conversion with lithium 
triethylborohydride and subsequent decomposition (46). Most [11C]CO chemistry utilizes 
transition metal catalysis (Pd, Ni for example), according to methodologies first developed by 
Heck et al (47, 48). These methods allows for the synthesis of a carbonyl group starting from 
an aryl/vinyl-halide or pseudo-halide and the appropriate amine or alcohol depending on 
whether an ester or amide is desired. The aryl-halide first undergoes an oxidative addition to 
the metal complex followed by a reaction with carbon monoxide and finally a reductive 
elimination by the amine/alcohol to regenerate the metal-ligand complex and yield the desired 
product. This sequence is referred to as a catalytic cycle. One limitation with 11C-carbonylation 
is the poor trapping of the gaseous [11C]CO2 or [
11C]CO in organic solvents. Recent 
developments in microfluidic reactors attempt to combat this by allowing for a finer 
distribution of gas in solvent (49, 50). 
11C-Methylation. [11C]CH3I or [
11C]CH3OTf  for 
11C-methylation reactions can be produced 
in a few different ways; [11C]CO2 can be converted into [
11C]CH3I in two different ways (a 
“wet” procedure and a gas phase procedure) as well as cyclotron produced [11C]CH4 being 
converted to [11C]CH3I (51). In the “wet” method [11C]CO2 is bubbled through a vessel of 
LiAlH4 in THF or Et2O reducing [
11C]CO2 to lithium [
11C]methoxide, which when treated with 
water gives [11C]methanol. Addition of hydroiodic acid gives the desired [11C]CH3I (52). In 
the gaseous method [11C]CO2 is pushed in to an oven with nickel and under pressure is reduced 
in presence of hydrogen gas from [11C]CO2 to [
11C]CH4, which can then be converted into 
[11C]CH3I in presence of I2 at 720°C. If using cyclotron produced [
11C]CH4 only the last step 
is needed (36). [11C]CH3I can be further converted into the more electrophilic [
11C]CH3OTf by 
passing through an column containing silver triflate at 160-190°C. 
1.3.2 Fluorine-18 chemistry 
Fluorine is not present in endogenous compounds and only in a fraction of pharmaceutical 
drugs, but due to its small size it can be incorporated in biologically active compounds by 
replacing hydrogen or hydroxyl groups with fluorine. As in [18F]2-fluoro-2-deoxy-D-glucose 
([18F]FDG), where a hydroxyl group is replaced by fluorine-18. [18F]FDG has long been used 
in cancer diagnostics (53). Cyclotron generated fluorine-18 can be produced via two different 
nuclear reactions, 18O(p,n)18F and 20Ne(d,α)18F (54-56). Both reactions can be utilized to 
produce [18F]F2 gas, which can be used in electrophilic labelling reactions. For nucleophilic 
reaction, [18F]F- is needed and can only be produced through the  18O(p,n)18F  reaction. One 
major difference between using [18F]F2  and [
18F]F- is that [18F]F2 will give a lower Am because 
F2 gas is added to the target for more effective release of radioactivity from the target. This 
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process is referred to as “carrier added”. Which is partly why [18F]F-  is more utilized and a 
wide scope of labeling strategies have been developed (57, 58).  
Electrophilic and radical radiofluorination. [18F]F2 is the most common source for 
electrophilic and radical fluorination and can be used directly or to generate secondary 
fluorination reagents. Xenon difluoride [18F]XeF2, can be produced in a reaction of [
18F]F2 with 
xenon in presence of nickel (59), and also from [18F]F- (60). N-[18F]fluorobenzenesulfonimide 
([18F]NFSI), is a useful reagent for fluorination reactions of ethers, aldehydes and silylalkenes 
(61). One of the most common electrophilic fluorination reagents, 1-chloromethyl-4-fluoro-
1,4-diazoniabicyclo [2,2,2]octane bis(triflate), Selectfluor, has been labeled from [18F]F2 to 
perform late-stage radiofluorinations (62). Because of the limitations on Am when using [
18F]F2, 
strategies for umpolung reactions using [18F]F- to perform electrophilic fluorination are being 
developed (63, 64). 
Nucleophilic radiofluorination. Nucleophilic aromatic substitution reaction (SNAr) and/or 
nucleophilic substitution 2 (SN2) reactions are the most common way of using [
18F]F-. [18F]F- 
is a useful nucleophile on its own but it’s generally produced from [18O]water. Water stabilizes 
the [18F]F- anion through hydrogen bonds and steps to activate [18F]F- by removal of [18O]water 
are needed. Target water containing [18F]F- ions is passed through a QMA Seppak cartiridge, 
an ion exchange column, that retains ions while eluted with water (65, 66). The trapped [18F]F- 
ions are eluted with aqueous acetonitrile solution containing a counter anion and a phase 
transfer catalyst, such as potassium carbonate and kryptofix 2.2.2. (67). Subsequent azeotropic 
evaporation of the water with acetonitrile improves the reactivity of the [18F]F- ion. With almost 
all water removed kryptofix 2.2.2. isolates the [18F]F- anion from the postassium cation and 
improves the reactivity of it by charge separation. [18F]F- can then be used as nucleophile in a 
SNAr to make [
18F]fluoroarenes, providing the aromatic ring is electron deficient with a suitable 
leaving group (LG) and an electron withdrawing substituent in either ortho- or para-position 
(68). The most common LGs in radiofluorination SNAr reaction are nitro and 
trimethylammonium groups but halides have also been used (69, 70). Because of the limitation 
to activated aromatic rings and suitable LGs, new techniques have been needed to enable late-
stage fluorination of pharmacologically active compounds. These include the use of iodonium 
salts, transition metal catalysts, and prosthetic group labeling (71-73). 
 
1.4 G-PROTEIN COUPLED RECEPTORS 
G-protein coupled receptors (GPCRs) are membrane proteins that mediate cellular signaling 
over cell membranes.(74) All GPCRs have a similar structure of seven subunits spanning the 
cell membrane The G-protein itself consists of three subunits (α, β, γ), where the α-subunit 
binds to the receptor. The receptor binds to a neurotransmitter and activates the G-protein on 
the other side of the membrane (75). GPCRs are not permanently coupled to the G-protein but 
exist in a series of conformational states with various affinity to ligands and efficacy upon 
binding (76). How many conformations exist and how these conformational changes occur is 
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unclear and may vary between different GPCRs. Complex models have been developed that 
also show the role of guanidine nucleotides (GDP/GTP) in activating G-protein to couple and 
uncouple from the receptor. Binding of an agonist is not enough to activate the GPCR but is 
dependent on the relative fraction of GTP and GDP bound to the G-protein. It has also been 
suggested that the binding of a ligand itself will conform and stabilize the GPCR in one state 
(77-79). In all these models it is generally considered that the G-protein coupled receptor is the 
agonist high affinity state, but the exact sequence of activation may vary (80). 
Several in vitro studies on GPCRs in the serotonergic system have shown that agonist binding 
is more affected by changes in receptor affinity states and that only a fraction of the total GPCR 
population is in an agonist high affinity state. These studies show a distinct dual affinity when 
evaluating the GPCR with an agonist, while an antagonist only shows one affinity (81-83). 
While the exact distribution between agonist high affinity and low affinity receptor complexes 
differ between receptor subtypes, the general idea is that endogenous substrate and agonist will 
almost exclusively bind to the high affinity state whereas an antagonist will bind more 
indiscriminately to both states (Figure 3).   
 
Figure 3. Simplified schematic view of antagonist/agonist interaction with GPCRs. The G-protein coupled 
receptor is generally considered the high affinity form of the receptor but it is not clear whether the coupling 
itself activates the receptor. Agonist binds with lower affinity to the low affinity receptor, whereas antagonist 
bind with equal affinity to both. 
PET studies on the dopaminergic system have shown higher displacement of an agonist 
radioligand than an antagonist radioligand by endogenous neurotransmitter, but this has not yet 
been replicated for the serotonergic system (84). 5-HT1B receptors have been shown to exist in 
an equilibrium of at least two separate affinity states, but it has not been determined how this 
equilibrium affects the binding of agonists and antagonists in vivo and if it can be quantified 
using PET (85).  
 
1.5 SEROTONERGIC SYSTEM 
Serotonin (5-HT) is a neurotransmitter and plays a vital role in several higher brain functions, 
such as emotion and cognition (86). The serotonergic system spans the entire CNS and much 
of the rest of the body, with 7 receptor families further divided into 14-16 subtypes of receptors 
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that exhibit different regional densities and physiological functions (87-89). 5-HT is a small 
and polar molecule that cannot pass the BBB but is instead synthesized in serotonergic neurons 
starting from the amino acid L-tryptophan. Tryptophan hydroxylase converts L-tryptophan first 
into 5-hydroxy-tryptophan (5-HTP), which can pass through the BBB, 5-HTP is subsequently 
decarboxylated into 5-HT and then stored and transported in vesicles along neurons to the 
synapses to activate the different physiological actions. Reuptake of 5-HT into the neuron cell 
is done by serotonin transporter channels (5-HTT). 5-HT is degraded by monoamine oxidase 
(MAO) to 5-hydroxyindoleacetic acid, which can be cleared out of the body through the 
kidneys (Figure 4). 5-HTT is an interesting target for inhibition with selective serotonin 
reuptake inhibitors (SSRI), where the aim is to prolong 5-HT signaling along the neuropathic 
system and has been studied with PET (90). MAO is further divided into MAO-A and MAO-
B, with PET radioligands developed for both enzymes (91). Synaptic concentrations need to 
be regulated to maintain normal brain function. This happens both through activation and de-
activation of release and uptake of 5-HT (92, 93). The 5-HT receptors function both as 
autoreceptors and heteroreceptors; autoreceptors regulate reuptake and continued release on 
the presynaptic neuron, heteroreceptors continue the signal post-synapse (94). Comparisons 
can be made with dopamine as they are both monoamine neurotransmitters active in the CNS 
and both the dopaminergic and serotonergic systems have been studied using PET (95).  
 
Figure 4. Schematic view of the serotonergic cycle in the neuron and synaptic cleft (96). L-tryptophan is 
converted into 5-HT, released through vesicles to the synapse and reuptake goes through the 5-HTT channels 
and subsequent degradation via MAO. 
1.5.1 5-HT1B receptors 
The 5-HT1B receptor is most widely expressed in the occipital cortex and globus pallidus in 
humans. In rodents the expression is slightly different with low expression in cerebrum but 
higher in the substantia nigra (97, 98). 5-HT1B was originally thought to be a substructure of 
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the human 5-HT1D receptor but has since been reclassified as a structurally unique 5-HT 
receptor (99). The 5-HT1B receptor expressed in rodent is structurally different from the human 
receptor, which leads to some drugs like sumatriptan having little to no effect in rodent but 
evident effect in humans whereas propanolol has the opposite species preference (100). The 5-
HT1B receptor is implicated in depression, anxiety and migraine and is an interesting target for 
PET studies focusing on changes in endogenous serotonin concentrations (101).  
5-HT1B receptors are present on neurons for other neurotransmitters, such as γ-aminobutyric 
acid (GABA), dopamine and acetylcholine as well as 5-HT. It is expressed as both an 
autoreceptor presynaptically and as a heteroreceptor postsynaptically (100). The 5-HT1B 
receptor couples to α-subunit of a G-protein that is negatively linked to adenylate cyclase, 
meaning that when the 5-HT1B receptor is activated it deactivates the cyclase enzyme. When 
expressed as an autoreceptor the adenylate cyclase controls further release of 5-HT into the 
synaptic cleft (102). A 5-HT1B agonist or endogenous 5-HT will therefore inhibit further release 
of 5-HT, whereas an antagonist will allow further release and initially increase the 5-HT 
concentration in the synaptic cleft. 5-HT1B also functions as a hetero-receptor on the receiving 
end of non-serotonergic neurons regulating further signaling along the receiving neuron (103, 
104). Recent crystal structures of human 5-HT1B receptor bound to agonist or antagonist show 
distinct structural changes to the receptor depending on the intrinsic activity of the ligand (105, 
106). Both agonist and antagonist will form hydrogen bonds with a threonine and asparagine 
amino acid in the deeper part of the binding site, but agonists and endogenous 5-HT will  allow 
one of the seven subunits to act as a “toggle switch” which has been considered to be the initial 
activation step of GPCRs (107). 
1.5.2 5-HT1B PET studies 
Two PET radioligands have been developed for imaging 5-HT1B receptors in brain, 
[11C]AZ10419369 and [11C]P943 (Figure 5) (108, 109).  [11C]AZ10419369 was selected from 
the same library of compounds used in this thesis and along with seven other candidates was 
evaluated in an initial PET study in monkey (110). Binding is highest in occipital cortex and 
globus pallidus and negligible in cerebellum. Cerebellum has been used as a reference region 
approximating non-specifically bound radioligand to quantify BPND. BPND is reportedly higher 
for [11C]AZ10419369 than for [11C]P943 but both of these radioligands have been shown to 
bind specifically to 5-HT1B in monkey brain. Both have shown to have high selectivity for 5-
HT1B receptors over other 5-HT receptors as well as being displaceable by fenfluramine-
induced changes in endogenous 5-HT concentrations (111, 112). 5-HT1B is an interesting target 
for studying fluctuation in synaptic 5-HT concentrations using PET and [11C]AZ10419369 has 
even shown to have a dose-dependent displacement with two separate doses of fenfluramine. 
Because fenfluramine is not approved for clinical studies, recent studies has been aimed at 
establishing protocol for 5-HT release using approved drugs (113). [11C]AZ10419369 has also 
been used in PET studies in pig (114). [11C]AZ10419096 and [11C]P943 has been used to study 
depression and Parkinson’s disease as well as migraine in clinical studies (115-118). Both 
[11C]AZ10419096 and [11C]P943 were originally described as antagonists but recently 
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[11C]AZ10419369, at least, has been reconsidered to be a partial agonist. Since it is proposed 
that an agonist and antagonist PET radioligand targeting a GPCR would have differing 
sensitivity to completion from endogenous neurotransmitters, 5-HT1B could be an interesting 
target for such studies with the development of PET radioligands of differing intrinsic activity 
(101). Both current PET radioligands for 5-HT1B receptor imaging utilizes the shorter lived 
carbon-11 radionuclide. An 18F-labeled radioligand would open up the research into 5-HT1B 
receptors to facilities even without a cyclotron on-site. 
 
                                                   
Ligand   [11C]AZ10419369   [11C]P943 
KI (nM)   0.4   1.2 
LogD   1.3   2.3 
BPND (occipital cortex)   1.52   0.71 
Figure 5. Prior to this thesis two PET radioligand has been developed to image 5-HT1B receptors in brain, 
[11C]AZ10419369 and [11C]P943. 
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2 AIMS 
The overall aim of this thesis was to expand the possibilities for imaging 5-HT1B receptors in 
brain by developing novel PET radioligands and to evaluate their ability to detect changes in 
endogenous 5-HT concentrations. 
 
The specific aims of this thesis were: 
1. To develop a full antagonist carbon-11 labelled 5-HT1B PET radioligand, paper I 
2. To develop a full agonist carbon-11 labelled 5-HT1B PET radioligand, paper II 
3. To evaluate if the intrinsic activity of a 5-HT1B PET radioligand influences its 
ability to detect changes in endogenous 5-HT concentrations, paper III 
4. To develop a fluorine-18 labelled 5-HT1B PET radioligand, paper IV 
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3 MATERIAL AND METHODS 
 
3.1 CHEMISTRY AND RADIOCHEMISTRY 
A brief summary of chemistry and radiochemistry procedures used in this thesis. All precursor 
synthesis procedures and radiochemistry methodology are described in detail in each 
constituent paper. 
3.1.1 Precursor synthesis 
Detailed experimental procedures and methods for each precursor synthesis can be found in 
their corresponding papers. All intermediate, precursors, and reference compounds were 
isolated and analyzed with high resolution mass spectrometry (HRMS) as well as 1H and 13C 
NMR. 
1H (400.13 MHz) and 13C (100.62 MHz) NMR spectra were recorded on an Advance 400 
instrument (Bruker) at room temperature in deuterated solvents.  NMR signals are reported as 
δ (ppm) downfield from the signal of tetramethylsilane.  HRMS data (ESI-TOF) were obtained 
at Bioorganic Chemistry Laboratory of NIDDK (NIH).  Optical rotations were measured on a 
P-1010 polarimeter (JASCO). 
3.1.2 Carbon-11 chemistry 
All radiosynthesis in papers I, III and IV as well as radiosynthesis of [11C]AZ11895987 in 
paper II were performed exclusively at the Karolinska Institutet, Stockholm, Sweden. 
Radiosynthesis of [11C]AZ11136118 for paper II were performed exclusively at the Molecular 
Imaging Branch, NIMH, Bethesda, MD, USA. 
11C-Methylation. Radiomethylations to produce [11C]AZ10419096, [11C]AZ11895987 and 
[11C]AZ12175002 were performed with the same general method: [11C]CH3OTf from 
cyclotron-generated [11C]CH4 was bubbled through a solution of desmethyl precursor (0.2-0.5 
mg) in acetone (0.5 mL) with NaOH (6.0µL, 0.5 M). After 2 min at ambient temperature, the 
solution was diluted with water (3 mL) and injected onto a reverse phase ACE C-18 HPLC 
column (250 × 10 mm; Advanced Chromatography Technologies Ltd) using a ratio of 
acetonitrile in aqueous NH4HCOOH (0.1M) appropriate for a product retention time of 8 to 12 
min. Acetonitrile was removed from collected fraction by evaporation (paper I) or by solid 
phase extraction eluting with 10% w/w ethanol(paper II and III) and formulated in sterile saline 
solution. 
11C-Carbonylation. [11C]CO generated from cyclotron produced [11C]CO2 was mixed under 
pressure (~3500 psi) with a mixture of Pd2dba3 (1.3 mg, 1.4 µmol), Xantphos (3.0 mg, 5.2 
µmol) and 4-iodophenyl methanesulfonate (2.4 mg, 8.1 µmol) in THF (80 µL). After reaction 
at 150°C during 3 min the solution was transferred into a second reaction vessel containing 
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(R)-8-(4-Methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-amine (3.2 mg, 13 µmol) and 
Bu3N (10 L, 42 µmol) in THF (50 µL).  The second reaction was heated from 67°C to 100°C 
while THF was evaporated. The remaining residue was dissolved in acetonitrile and water 
before being injected onto a Luna C18 column (10 µm, 10  250 mm; Phenomenex; Torrance, 
CA) eluted with a gradient of 90-55% of 0.2% aqueous NH4OH (pH = 8.5) in acetonitrile. The 
fraction containing [11C]AZ11136118 eluated between 17 and 19 min. Acetonitrile was 
removed by evaporation and [11C]AZ11136118 was formulated in sterile saline solution.  
3.1.3 Fluorine-18 chemistry 
Cyclotron produced [18F]F- ions, K2CO3 (1.8 mg, 13 µmol) and kryptofix 2.2.2 
(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8.8.8]hexacosane-K2.2.2) (9.8 mg, 26 µmol) in 
water (85 µL, 18 MΩ) and acetonitrile (2 mL) were eluted into a glass reaction vessel (10 mL). 
The solvent was removed by azeotropic evaporation with acetonitrile at 140°C under 
continuous nitrogen flow (70 mL/min). The borate precursor, (60 µmol), and [Cu(OTf)2(py)4] 
(5 µmol) were dissolved in DMF (500 µL) and added manually to the reaction vessel. The 
closed reaction vessel was heated at 120°C for 10 min. The reaction mixture was then cooled 
to room temperature and diluted with water (3 mL) before being injection onto a reversed phase 
ACE C-18 HPLC column (250 × 10 mm; Advanced Chromatography Technologies Ltd). 
Excess [18F]F- was washed out with water over 5 min before switching to a mobile phase of 
40% acetonitrile in aqueous NH4HCOOH (0.1M) containing 0.01% sodium ascorbate. 
[18F]AZ10419096 eluted at 12 min after changing mobile phase. Acetonitrile was removed by 
solid phase extraction and [18F]AZ10419096 was formulated in sterile saline solution with 10% 
w/w ethanol. 
3.1.4 Radiochemical purity and Am analysis 
Radiochemical purity of the formulated products were determined with reversed phase HPLC 
on either ACE 5 C18-HL column (3.9 × 300 mm, 10 µm; Advanced Chromatography 
Technologies Ltd) at Karolinska Institutet or a Luna C18 column (10 µm, 4.6  250 mm; 
Phenomenex) at NIMH, with eluate monitored in series for absorbance at 254 nm and 
radioactivity.  For the analysis, the column was eluted using an optimized ratio of acetonitrile 
in an appropriate aqueous solution. The products were identified by their co-elution with 
corresponding reference samples. 
Am was the radioactivity at EOS of the radioligand (GBq) divided by the amount of the 
associated carrier substance (µmol). Each sample was analyzed three times by reversed phase 
HPLC on either ACE 5 C18-HL column (3.9 × 300 mm, 10 µm; Advanced Chromatography 
Technologies Ltd) at Karolinska Institutet or a Luna C18 column (10 µm, 4.6  250 mm; 
Phenomenex) at NIMH, and compared with a sample of reference compound of known 
concentration. The average area under the curve for the UV absorbance for each sample was 
compared to that of the reference sample to determine the amount of carrier substance in each 
sample.  
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3.2 PET EXPERIMENTAL PROCEDURES 
All PET measurements for [11C]AZ11136118 (paper II) were performed at the Molecular 
Imaging Branch, NIMH, Bethesda, MD, USA. All other PET measurements were performed 
at the Karolinska institutet, Stockholm, Sweden. 
3.2.1 Non-human primates 
Karolinska Institutet (papers I, II, III and IV). All PET studies in non-human primates (NHP) 
at the Karolinska Institutet were approved by the Animal Ethics Committee of the Swedish 
Animal Welfare Agency (Dnr N185/14) and were performed according to the relevant 
guidelines of the Karolinska Institutet (“Guidelines for Planning, Conducting, and 
Documenting Experimental Research” (Dnr 4820/06-600) and “Guide for the Care and Use of 
Laboratory Animals”.  
Cynomolgus monkeys were supplied by Astrid Fagraeus Laboratory of the Swedish Institute 
for Infectious Disease Control (Solna, Sweden). Anesthesia was initiated via intramuscular 
injection of ketamine hydrochloride (ca. 10 mg/kg) and maintained after endotracheal 
intubation by administration of a mixture of sevoflurane, oxygen and medical air. The monkeys 
were observed continuously during the days of PET measurements. Body temperature was 
maintained by Bair Hugger-Model 505 and monitored with an esophageal thermometer. Heart 
and respiration rates were continuously monitored by using PC-VetGard ™ system. The 
monkey head was fixed in position throughout PET scanning. In each PET measurement a 
sterile physiological saline buffer solution containing the radioligand was injected 
intravenously during 5 s with simultaneous start of PET data acquisition. Radioactivity in brain 
was measured continuously for 123 min according to a preprogrammed series of 34 frames.  
In pretreatment PET measurements using AR-A00002, a baseline PET measurement was 
followed on the same day three hours later by a second PET measurement with AR-A00002 
(2.0 mg/kg) administered 30 min before of radioligand. 
In displacement PET measurement using fenfluramine, a baseline PET measurement was 
followed on the same day three hours later by a second PET measurement with fenfluramine 
(1.0 or 5.0 mg/kg) administered 15 min (paper III) or 30 min (paper I) after the radioligand. 
Molecular Imaging Branch, NIMH (paper II). The PET imaging experiments in nonhuman 
primates at NIMH were performed in accordance with the Guide for Care and Use of 
Laboratory Animals and were approved by the National Institute of Mental Health Animal Care 
and Use Committee(119). 
One single rhesus monkey (Macaca mulatta) was used for PET scan sessions in which the 
monkey was initially anesthetized with ketamine (10 mg/kg) and then maintained in anesthesia 
with 1.5% isoflurane. PET images of brain were acquired with a microPET Focus 220 scanner 
(Siemens Medical Solution; Knoxville, TN) for 90 min with scan durations ranging from 30 s 
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to 5 min.  The position of the head was fixed using a stereotaxic frame.  Electrocardiogram, 
body temperature, heart, and respiration rates were monitored throughout the experiments.   
3.2.2 Rodents 
Six rats (Sprague Dawley) were used in PET imaging experiments. The rats were anesthetized 
with ketamine (10 mg/kg) and then maintained in anesthesia with 1.5% isoflurane for PET 
scanning sessions after bolus intravenous administration of radioligand. PET images of brain 
were acquired with a microPET Focus 220 scanner (Siemens Medical Solution; Knoxville, TN) 
for 90 min.  The PET data analysis was performed using PMOD (PMOD Technologies Ltd.; 
Zurich, Switzerland). 
Three rats (Sprague Dawley) were used in ex-vivo PET measurements. Tariquidar (8 mg/kg) 
was injected intravenously through the penile vein 7 min before likewise injection of 
radioligand.  The rats were anesthetized with 1.5% isoflurane in oxygen and sacrificed via 
thoracotomy at 30 min after injection. The brains were harvested and subsequently weighed 
and formulated into samples subjected to radio-analysis using radio-HPLC. 
P-gp/BCRP knockout (KO) mice (Taconic Farm, Germantown, NY) were anesthetized with 
1.5% isoflurane and oxygen and sacrificed via thoracotomy at 30 min after radioligand 
injection.  Blood was drawn from the myocardium, and the forebrains and cerebella were 
subsequently harvested.  The tissues were weighed and immediately subjected to analysis with 
radio-HPLC. 
3.2.3 Radiometbolite analysis and plasma free fraction 
Karolinska Institutet. Venous blood samples (2 mL) were obtained manually at 4, 15, 30, 60, 
90, and 120 min after injection of radioligand for measurement of total radioactivity in whole 
blood and plasma and for radiometabolite analysis (120, 121). The concentration of parent 
radioligand was measured with HPLC on an ACE 5 C18-HL column (3.9 × 300 mm, 10 µm; 
Advanced Chromatography Technologies Ltd), after separating plasma from whole blood.  
Recovery of radioactivity from the system was calculated by taking an aliquot (2 mL) of the 
eluate from the HPLC column and measuring and dividing it with the amount of total injected 
radioanalyte (decay-corrected). 
Molecular Imaging Branch, NIMH (paper II). Arterial blood samples were drawn for analysis 
of radiometabolites in plasma and for determination of a radiometabolite-corrected arterial 
input function.  Samples (0.5−1 mL each) were drawn at 15-s intervals until 120 s, followed 
by 0.5- to 4-mL samples at 3, 5, 10, 30, 60, 90, and 120 min.  The concentration of parent 
radioligand was measured with HPLC on an X-terra column (10 µm, 7.8 × 300 mm; Waters 
Corp.), after separating plasma from whole blood 
Plasma free fraction (fP). Manual blood samples for measurement of the fraction of unchanged 
radioligand in plasma, were obtained twice in the first 10 min, and then once every 10 min. 
The fraction was determined by HPLC on either ACE 5 C18-HL column (3.9 × 300 mm, 10 
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µm; Advanced Chromatography Technologies Ltd) at Karolinska Institutet or X-terra column 
(10 µm, 7.8 × 300 mm; Waters Corp.) at NIMH, with radio detection after filtration and 
formulation. 
3.2.4 PET data analysis 
T1-weighted brain MR images were manually co-registered to the average PET images and 
regions of interest (ROIs) were delineated manually for the whole brain, occipital cortex, 
globus pallidus, caudate nucleus, putamen, ventral striatum, cerebellum, frontal cortex, mid 
brain, thalamus, and hippocampus. Regional uptakes are reported as standardized uptake value 
(SUV) or %SUV, calculated as uptake (Bq/mL)/injected radioactivity (Bq) × body weight (g). 
Binding ratio was calculated as SUVregion/SUVcerebellum and specific binding ratio as 
(SUVregion/SUVcerebellum) −1. 
Regional BPND were calculated by using the simplified reference tissue model (SRTM) (122). 
Cerebellum was used as reference region because this region has negligible density of 5-HT1B 
receptors (123). The specific binding of radioligand to 5-HT1B receptors was defined as the 
difference between the total radioactivity concentrations in the target brain regions and the 
cerebellum. 
 
3.3 PHYSIOCHEMICAL PROPERTIES ANALYSIS 
Apparent pKa. [
11C]AZ11136118 was evaluated in phosphate buffer between pH 3.0 and 10.5 
in 0.5 increments. The apparent pKa value was determined as the pH value where the 
concentration of ionized and non-ionized [11C]AZ11136118 were equal as measured by 
reversed phase HPLC on a X-terra column (10 µm, 7.8 × 300 mm; Waters Corp.). 
LogD7.4 determination. The relative distribution of [11C]AZ11136118 between an aqueous 
phosphate buffer (pH 7.4) and 2-octanol was evaluated by radio-analysis using reversed phase 
HPLC on a X-terra column (10 µm, 7.8 × 300 mm; Waters Corp.). The logarithmic fraction of 
the compound concentration in octanol over the concentration in the aqueous buffer represents 
logD7.4. 
Quantum chemical calculations. The geometry and energetics of compound conformers in 
the presence of a water molecule were obtained with quantum chemical calculations. The 
geometry was refined in Gaussian 09 software (124). Each conformer represents the geometry 
optimized structures of the compounds in respect to enthalpy (ΔH), Gibbs free energy (ΔG), 
and dipole moment with the protonated N-methyl-piperazine. Conformer a has the piperazine 
in a stable chair conformation with the methyl-group facing the amide, conformer b has rotated 
the piperazine 180° between the piperazine and the bicyclic ring with the amide oxygen facing 
away from the piperazine and for conformer c the amide has been rotated 180° between the 
carbonyl and the bicyclic ring (Figure 6). 
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Figure 6.  Geometry optimized structures of conformers of AZ11895987 (5) with the protonated N-methyl-
piperazine and a water molecule.  φ1 and φ2 are the dihedral angles centered on the respective C−N bond of a and 
C−C bond of b.  Atoms are colored as follows: white, hydrogen; green, carbon; blue, nitrogen; red, oxygen.  
Dashed lines indicate the H-bonding distances (< 2.0 Å).   
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4 RESULTS AND DISCUSSION 
 
                                 
Ligand AZ10419369 AZ10419096 AZ11895987 AZ11136118 AZ12175002 
KI (nM) 0.4 0.13 0.46 0.25 0.6 
LogD 1.3 2.3 2.1 2.2 1.5 
EC50 (nM)   0.98 0,.7 0.97 
IC50 (nM) 50 2    
Antagonist (%) 53.2 190 -16 -3.1 18 
Agonist (%) 48  113.3 112.8 77.1 
Radionuclide C-11 C-11 or F-18 C-11 C-11 C-11 
Figure 7. Structures and in vitro data for the ligands used in this thesis. In vitro data provided by AstraZeneca. 
4.1 FULL ANTAGONIST 5-HT1B PET RADIOLIGAND (PAPER I) 
A summary of the results from paper I. 
AZ10419096 was identified for its favorable affinity, lipophilicity and antagonist efficacy from 
a library of over 3000 compounds provided by AstraZeneca (Figure 7). 
4.1.1 Chemistry and radiochemistry 
A sample of AZ10419096 was de-methylated using 1-chloroethyl chloroformate to provide the 
desmethyl precursor in enough yield (36%), which in turn was labeled with carbon-11 using 
[11C]methyl triflate (Scheme 1). [11C]Methyl triflate was added to a solution of desmethyl-
AZ10419096 in acetone and NaOH with a reaction time of 2 min at ambient temperature. 
Purification using reverse phase HPLC followed by formulation in sterile saline gave 
[11C]AZ10419096 in sufficient amount (1004±102 MBq), Am (584±82 GBq/µmol) and purity 
(>98%) for use in PET measurement in NHP.  An initial problems with radiolysis of the product 
was controlled by adding 0.01% sodium ascorbate to the mobile phase, which carried through 
to the formulated product. 
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Scheme 1. Synthesis and radiolabeling of [11C]AZ10419096. 1. 1-Chloroethyl-chloroformate, DCE. 2. 
Methanol, reflux. 36% yield. Radiolabeling. [11C]CH3OTf, NaOH, acetone.  
4.1.2 PET measurements 
[11C]AZ10419096 was used for PET measurements in NHP. In baseline PET measurements, 
radioactivity entered brain quickly and reached a maximum uptake after about 10 min (Figure 
8 and 9A). The radioactivity showed a heterogeneous distribution in brain consistent with 
earlier reported regional concentrations of 5-HT1B receptors (97). BPND was calculated using 
SRTM with cerebellum as reference region to be 0.92 for occipital cortex and 1.22 for globus 
pallidus. In pretreatment PET measurement using AR-A000002 (2.0 mg/kg) administered 30 
min prior to [11C]AZ10419096, binding was blocked by 88% in occipital cortex and 90% in 
whole brain showing high specific binding to 5-HT1B receptors in brain. (Figure 9B). In 
displacement PET measurements, fenfluramine (5.0 mg/kg) was administered 30 min after the 
administration of [11C]AZ10419096 and 40% reduction of binding was observed in occipital 
cortex between 45 and 93 min, in globus pallidus only a minor reduction could be observed 
(Figure 8 and 9C). 
 
Figure 8. PET summation images (45-93 min) using [11C]AZ10419096. Top row; PET summation image from 
baseline PET measurement, bottom row; PET summation images from PET measurement with fenfluramine (5.0 
mg/kg) given 30 min after radioligand. 
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Figure 9. Time-activity curves from PET measurements (%SUV, 0-93 min) using [11C]AZ10419096. A. 
Regional time-activity curves in baseline measurements, B. Regional time-activity curve after pretreatment with 
AR-A000002 (2.0 mg/kg), C. Specific binding ratio in occipital cortex at baseline (solid) and displacement PET 
measurements (hollow). Arrow denotes injection time of fenfluramine (5.0 mg/kg). 
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Radiometabolite analysis of plasma sampled during PET measurements showed at 60 min after 
administration, parent radioligand represented ~55% of radioactivity in plasma (Figure 10). 
The percentage of radioligand free in plasma was ~30%. 
 
Figure 10. Radiometabolism of [11C]AZ10419096 and [18F]AZ10419096 in monkey baseline PET measurement. 
%Parent denotes percentage of radioactivity in blood plasma from unchanged radioligand. 
4.1.3 Discussion 
[11C]AZ10419096 was selected as a full antagonist from in vitro data (Figure 7) and the initial 
evaluation showed high specific binding to 5-HT1B receptors in brain and sensitivity towards 
increased endogenous 5-HT concentrations induced by fenfluramine. As a full antagonist, 
[11C]AZ10419096 could be useful in future PET studies of imaging differences in high and low 
affinity state 5-HT1B receptors. 
 
4.2 FULL AGONIST 5-HT1B PET RADIOLIGANDS (PAPER II) 
A summary of the results from paper II. 
Both AZ11895987 and AZ11136118 were identified from the same library as AZ10419096 
using the same criteria with the exception of agonist efficacy instead of antagonist efficacy. 
4.2.1 Chemistry and radiochemistry 
Reference samples and precursor for AZ11895987 as well as reference sample of AZ11136118 
were provided by AstraZeneca.  
[11C]AZ11895987. [11C]Methyl triflate from cyclotron-produced [11C]CH4 was bubbled 
through a solution of desmethyl-AZ11895987 in acetone and NaOH with a reaction time of 2 
min at ambient temperature (Scheme 2). Purification with preparative HPLC followed by 
formulation in sterile saline gave [11C]AZ11895987 in sufficient amount (1025 MBq), Am (654 
GBq/µmol) and purity (>98%) for use in PET measurement in NHP. 
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Scheme 2. Radiolabeling of [11C]AZ11895987.  
 
Scheme 3. Synthesis of (R)-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-amine. Isolated yields for 
each of the intermediates, i) 85% ii) 92% iii) 83% iv) 68% v) 81% vi) 90%. 
[11C]AZ11136118. AZ11136118 was unstable in the demethylation reaction described in paper 
I and was synthesized from commercial starting material (Scheme 3). A multi-step synthesis 
was designed and performed in good overall yields (36% over 6 steps) to give enantiomerically 
pure (R)-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-amine. Starting from 8-
methoxy-2-tetralone, the first step was a reductive amination with benzylamine followed by 
addition of (R)-menthyl group both as protection and as a chiral derivatization agent. The 
methoxy-group was made into a more reactive LG by demethylation followed by reaction with 
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triflate anhydride. The triflate was replaced by methyl-piperazine in a Buchwald-Hartwig 
amination. At this point the diastereomers could be derivatized by flash column 
chromatography. Both diastereomers were deprotected in two steps and their respective optical 
rotations were compared with a sample of enatiomerically pure (R)-8-(4-methylpiperazin-1-
yl)-1,2,3,4-tetrahydronaphthalen-2-amine provided by AstraZeneca. 
4-Iodophenyl methanesulfonate was synthesized in one step from 4-iodophenol in quantitative 
yields (Scheme 4).  
Radiolabelling of [11C]AZ11136118 was optimized in a 2-step synthesis using [11C]CO in a 
pressurized loop with 4-Iodophenyl methanesulfonate, Pd2dba3 and Xantphos in THF (Scheme 
4). This mixture was pumped into a second vessel containing (R)-8-(4-methylpiperazin-1-yl)-
1,2,3,4-tetrahydronaphthalen-2-amine in THF with trace amount of TBA. Subsequent 
purification by preparative HPLC and formulation in sterile saline yielded [11C]AZ11136118 
in sufficient amounts (1240 ± 347 MBq), Am (83 ± 51 GBq/ µmol) and purity (>95%) for use 
in PET measurements in NHP and rodent. 
 
 
Scheme 4. Synthesis of 4-iodophenyl methanesulfonate (100% yield) and subsequent radiolabeling of 
[11C]AZ11136118. 
4.2.2 PET measurements and radioligand evaluation 
PET experiments in NHP. [11C]AZ11895987 and [11C]AZ11136118 were used in a baseline 
PET measurement and showed low brain uptake with no heterogeneous regional distribution 
detected. [11C]AZ11136118 was further investigated in NHP by blocking the efflux transporter 
P-gp in the BBB using tariquidar (8.0 mg/kg), which increased the brain uptake from 0.1 SUV 
to 0.4 SUV. Still no heterogeneous distribution in brain could be detected.  In an additional PET 
measurement using both tariquidar (8.0 mg/kg) and A-RA000002 (2.0 mg/kg) no blocking of 
any specific binding could be detected. The plasma free fraction for [11C]AZ11136118 and 
[11C]AZ11895987 was 18.0 ± 0.8% (n = 3) and 50.30 ± 0.03% (n = 6) respectively. 
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PET experiments in rodents. [11C]AZ11136118 was further investigated in rat but no 5-HT1B 
receptor specific binding could be detected in rats treated with tariquidar (8.0 mg/kg), and AR-
A000002 (2.0 mg/kg). Ex-vivo PET measurements with rats and mice showed >95% of 
radioactivity present in brain was parent compound.   
Conformational calculations The apparent pKa of [
11C]AZ11136118 was measured to be 8.00 
± 0.03 (n = 3) and logD7.4 was 2.01 ± 0.01 (n = 6) indicating that the molecule will be protonated 
at physiological pH. Computational calculation were made to determine the most likely 
structural conformation of both [11C]AZ11136118 and [11C]AZ11895987 along with previous 
successful 5-HT1B PET radioligands. These showed that unlike [
11C]AZ10419096, 
[11C]AZ10419369 and [11C]P943, both agonists are unlikely to form an intramolecular H-bond 
between the piperazinyl-N and the amide through a water molecule. The data from these 
calculations show that without this H-bond the dipolar moment is higher because it localizes 
the formal charge of the compound to the piperazinyl-N and hinders passive BBB diffusion 
(Table 2). Table 2 shows that the H-bonding conformations having the lowest dipole moment 
for each compound. But for [11C]AZ11136118 and [11C]AZ11895987 it also increases the ΔG 
and reduces the conformational stability. The BBB-penetrant radioligands all have a dipole 
moment below 24 Debye in their energetically favorable conformation. 
Table 2. Energetics and dipole moment of the conformers of the published 5-HT1B PET radioligands. 
Conformers were obtained as described in section 3.3. Conformation a and b refers to open conformations and c 
refers to the H-bonding conformation. 
Conformer  
Enthalpy  
Gibbs free 
energy  Dipole moment  
(Debye) (ΔH) (ΔG)  
(kcal/mol) (kcal/mol) 
AZ10419369a 0 0 30.9 
AZ10419369b 2.1 2.3 24.4 
AZ10419369c -1.6 -1.2 18.0 
P943a 0 0 22.5 
P943b −2.3 −0.9 15.5 
AZ10419096a 0 0 32.1 
AZ10419096b 2.9 3.4 25.1 
AZ10419096c −2.0 −1.2 20.3 
AZ11136118a 0 0 24.1 
AZ11136118b 0.7 3.6 18.0 
AZ11136118c −1.0 1.8 16.3 
AZ11895987a 0 0 30.9 
AZ11895987b −0.2 1.8 14.4 
AZ11895987c −1.8 0.2 12.6 
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4.2.3 Discussion 
The project at AstraZeneca, from which the data set used to select the candidate came from, 
was focused on finding an antagonist which meant that very few high affinity full agonist 
compound were available and limited the study to just two compounds. The low brain uptake 
and poor regional distribution of [11C]AZ11895987 was not fully investigated and the more 
rigorous investigation into the poor results of [11C]AZ11136118 gave no clear reason for the 
agonists poor performance. While blocking the P-gp efflux pump increased the brain uptake, 
no regional distribution indicative of specific binding could be seen. The postulated possible 
H-bond in BBB penetrant 5-HT1B PET radioligand needed further investigation to be 
conclusive. PET measurements in rodent were able to determine that no radiometabolites were 
entering the brain. 
 
4.3 INTRINSIC ACTIVITY IN 5-HT1B PET RADIOLIGANDS (PAPER III) 
A summary of the results from paper III. 
[11C]AZ10419096, [11C]AZ12175002 and [11C]AZ10419369, three high-affinity 11C-labeled 
5-HT1B PET radioligands with differing intrinsic activity were used in PET measurements in 
monkey to evaluate their sensitivity to fenfluramine induced changes in endogenous 5-HT 
concentrations. 
4.3.1 Radiochemistry 
[11C]AZ12175002 and [11C]AZ10419096 were both labelled through the 11C-methylation 
procedure described in section 3.1.2 in sufficient amounts (1946 ± 704 MBq  and 1125 ± 360 
MBq respectively), Am (974 ± 636 GBq/µmol and 639 ± 205 GBq/µmol respectively) and with 
high radiochemical purity (>97%) for use in PET measurements in NHP. 
4.3.2 PET measurements 
One monkey was used in a baseline PET measurement using [11C]AZ12175002 followed 2.5 
hours later by a pretreatment PET measurement using AR-A000002 (2.0 mg/kg) given 30 min 
prior to injection of radioligand. Binding of [11C]AZ12175002 was blocked by 90% in occipital 
cortex showing high specific binding to 5-HT1B receptors. 
Two monkeys were used in baseline PET measurements followed three hours later by a 
displacement PET experiment using fenfluramine (1.0 and 5.0 mg/kg) given 15 min after 
injection of radioligand. Changes in regional BPND for occipital cortex between 45 and 123 min 
were calculated using SRTM. At the higher dose of fenfluramine the relative displacement of 
radioligand increased with increased agonistic efficacy (Figure 11). The agonistic 
[11C]AZ12175002 showed a decrease in BPND of 60% compared to 52% for [
11C]AZ10419369 
and 40% for the full antagonist [11C]AZ10419096.(112, 125) At the lower dose of fenfluramine 
this correlation was not evident. At this dose, the antagonistic [11C]AZ10419096 shows the 
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lowest decrease (19%) but the agonistic [11C]AZ12175002 only slightly higher (21%) and the 
mixed efficacy [11C]AZ10419369 the highest (30%). All three radioligands showed dose 
dependent displacement. 
 
Figure 11. Displacement of radioligand by endogenous 5-HT in percent using fenfluramine (1.0 mg/kg and 5.0 
mg/kg). Results for [11C]AZ10419096 at fenfluramine (5.0 mg/kg) are based on one monkey (125). Results for 
[11C]AZ10419369 at both doses are based on three monkeys (112). All other results are based on 2 monkeys. 
The BPND (45−123 min) calculated for the three radioligands also increases with increasing 
antagonistic efficacy from 0.9 for the agonistic [11C]AZ12175002 and 1.9 for 
[11C]AZ10419369 to 3.2 for the antagonistic [11C]AZ10419096. A higher uptake in cerebellum 
for [11C]AZ12175002 could also be detected. 
4.3.3 Discussion 
The evaluation of how intrinsic efficacy in a 5-HT1B PET radioligands affects its sensitivity 
towards competition from endogenous 5-HT was hampered by the lack of a full agonist 
radioligand (see section 4.2). Instead, [11C]AZ12175002 was used, a highly agonistic 
compound with some antagonist effect (110). The results were not enough to conclusively 
uphold or dismiss the theory that an agonist PET radioligand would be displaced to a higher 
extent by endogenous 5-HT competition than an antagonist. But considering the challenges in 
undertaking such a PET study, the results establish some parameters for future extended 
studies. Three structurally similar high affinity 5-HT1B PET radioligands were developed, with 
differing intrinsic activity. All three displayed a dose-dependent sensitivity towards 
fenfluramine induced changes in synaptic 5-HT concentrations. A dose range of fenfluramine 
was established within which an extended study can take place. The problem of comparing 
data from different individuals was apparent and should be avoided, instead multiple PET 
measurements in each individual are desired. Another trend is also evident; the BPND increases 
with increasing antagonist activity. This follows the idea that an antagonist would have a higher 
concentration of available receptors to bind to than an agonist, as an antagonist can bind 
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indiscriminately to all affinity states of the receptor. Any exact quantification of this is not 
feasible as several unknown parameters are involved. A problem in visualizing the high and 
low affinity state of GPRCs in vivo is the difficulty in developing agonist PET radioligands 
because the affinity measured in in vitro assays may not accurately capture the true affinity and 
selectivity in a dynamic system in presence of several subtypes of the receptor (126). As an 
agonist tends to have a closer structural similarity to the endogenous ligand, off-target binding 
is an increasing risk for agonist PET radioligands for 5-HT receptors, as there are several 5-HT 
receptor subtypes with whom endogenous 5-HT interacts. It is also unclear if the distinct 
difference between high and low affinity seen in vitro can be replicated in vivo where a receptor 
could potentially be involved in several conformations within the duration of a PET 
measurement (127, 128). 
4.4 FLUORINE-18 5-HT1B PET RADIOLIGAND (PAPER IV) 
A summary of the results from paper IV. 
[18F]AZ10419096 is structurally identical to [11C]AZ10419096 only differing in type of 
radionuclide used. The structure of AZ10419096 contains two fluorine substituents either of 
which might be exchanged potentially with fluorine-18. The choice of fluorine to exchange 
was directed by the availability of starting material from AstraZeneca. 
4.4.1 Chemistry and radiochemistry 
The available chloro-analog of AZ10419096 was used to synthesize the boronate precursor in 
good yield (91%). The precursor is susceptible to de-borylation in protic solvents and could 
not be purified with chromatographical techniques, but instead had to be isolated by a 
simplified crystallization method. This meant the purity of the precursor could not be accurately 
measured by HPLC. Radio-fluorination was performed using copper-catalyzed fluorination of 
the borate, a recently developed methodology (129). The radiofluorination reaction only gave 
low RCY (<5%), perhaps linked to the instability of the precursor, but was able to produce 
sufficient amounts (350 MBq) of high radiochemical purity (> 97%) and Am (150 GBq/µmol) 
for use in PET measurements in NHP. 
 
Scheme 5. Synthesis scheme of precursor and radiolabeling of [18F]AZ10419096. 
  29 
4.4.2 PET measurements 
A baseline PET measurement using [18F]AZ10419096 showed brain uptake and regional 
distribution consisted with the structurally identical [11C]AZ10419096 (Figure 12 and 13A). 
The ratio of radioactivity in ROIs to cerebellum peaked within 60 min and remained at that 
level thereafter (Figure 13B). BPND was calculated using SRTM with cerebellum as reference 
region to be 1.37 for occipital cortex and 1.54 globus pallidus. In pretreatment PET 
measurement using AR-A000002 (2.0 mg/kg) administered 30 min prior to [18F]AZ10419096, 
binding was blocked by 80% in occipital cortex and 70% in whole brain showing high specific 
binding to 5-HT1B receptors in brain (Figure 12 and 13C). 
 
Figure 12. PET summation images (0−123 min); Top row; PET summation images from baseline PET 
measurement using [18F]AZ10419096; Bottom row; PET summation images from PET measurement with AR-
A000002 (2.0 mg/kg) given 30  min before [18F]AZ10419096. 
Radiometabolite analysis of plasma sampled during PET measurements showed at 60 min after 
administration, parent radioligand represented ~ 50% of radioactivity in plasma (Figure 10). 
The percentage of radioligand free in plasma was ~30%.  
4.4.3 Discussion 
[18F]AZ10419096 is the first fluorine-18 PET radioligand for imaging 5-HT1B receptors in 
brain. It shows favorable pharmacological properties and could be a useful tool in further 
research of serotonergic system. The chemistry needs improvement as both precursor synthesis 
and radiofluorination methodology met with challenges. The stability of the borate precursor 
was low which most likely led to the radiofluorination only working in low radiochemical 
yields. 
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Figure 13. A. Regional time-activity curves from baseline PET measurement (SUV, 0-123 min) using 
[18F]AZ10419096. B. Regional binding ratio from baseline PET measurement using [18F]AZ10419096. C. 
Regional time-activity curves from pretreatment PET measurement using [18F]AZ10419096, AR-A000002 (2.0 
mg/kg) was given 30 min before the radioligand. 
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4.5 ADDITIONAL COMMENTS AND DISCUSSION 
Some additional comments and discussion points not directly linked to one specific paper. 
4.5.1 Chemistry 
11C-N-methylation using [11C]CH3OTf was successfully used to produce [
11C]AZ10419096 as 
well as [11C]AZ11895987 and [11C]AZ12175002 in sufficient yields and Am and with high 
radiochemical purity. The desmethyl precursor for [11C]AZ10419096 used in paper I could be 
synthesized from a reference sample in high purity but in low yields. This approach was also 
attempted with AZ11136118 and a few other non-published compounds. However, the 
demethylation reaction using 2-chloroethyl chloroformate in most cases gave high amounts of 
by-product and little-to-no desired product. A more consistently successful approach, albeit 
more time-consuming, proved to be to synthesize the desmethyl-precursor from simpler 
starting material using a protected piperazinyl group, as was the case for both 
[11C]AZ10419096 and [11C]AZ12175002 used in paper III. 
4.5.2 Agonist 5-HT1B PET radioligands 
In his thesis, no full agonist was successfully developed as a useful 5-HT1B PET radioligand. 
Whether a full agonist can be developed remains to be seen, as the full agonists 
[11C]AZ11136118 and [11C]AZ11895987 failed to enter the brain in any useful amounts even 
with efflux transporter P-gp blocked. A highly agonistic PET radioligand previously identified 
was further characterized, [11C]AZ12175002.  [11C]AZ11895987 and [11C]AZ12175002 have 
close structural similarities, only differing in the direction and stereochemistry of the central 
amide as well as the oxygen in bicyclic ring system (Figure 7). They also share a strong 
structural similarity with AR-A000002, which is used in this thesis to block the 5-HT1B 
receptors in brain and therefore is able to pass through the BBB, in higher doses than a PET 
micro-dose at least.  
In paper II, a proposed reason for the poor brain uptake was the inability of [11C]AZ11136118 
and [11C]AZ11895987 to form an energetically favorable H-bond between the protonated 
piperazinyl nitrogen and the amide, aided by a water molecule. This H-bond lowers the dipole 
moment of the molecule and attenuates the formal charge of the protonated methyl-piperazine. 
According to additional quantum calculations performed later for this thesis, [11C]AZ12175002 
seem equally unlikely to form a H-bond as [11C]AZ11895987 as evidenced by the higher free 
energy (ΔG) of the H-bond conformation c (Table 3). AR-A000002 also seem unlikely to form 
an H-bond but has never been used in a micro-dose so its brain uptake might be low but enough 
to have effect in a higher dose. The comparatively similar results for non-BBB-penetrant 
[11C]AZ11895987 and BBB-penetrant [11C]AZ12175002 shows that this explanation is overly 
simplistic and that other factors must also be considered. Firstly, as a basis for this idea was the 
measured apparent pKa of [
11C]AZ11136118 and it was assumed that all methyl-piperazinyl 
groups would have similar pKa values around 8.0. With a lower pKa value the need for 
attenuating a formal charge would not be needed as the piperazinyl-N would not be protonated. 
Secondly, the calculations only considers one intramolecular interaction and potentially there 
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could be other interactions to consider. Thirdly, the poor brain uptake for full agonists could be 
due to other issues entirely, such as lack of binding to 5-HT1B receptors and/or active transport 
out of the brain by efflux transporter other than P-gp. One such possibility is that an agonist 
with high affinity to a 5-HT receptor would potentially also be a substrate for 5-HTT mediated 
transport inside the neuron and subsequently out from brain. 5-HTTs expression along the 
axons would also prevent the radioligand from ever reaching the 5-HT1B receptors in the 
synapse.(130)  
Table 3. Quantum calculations of AR-A000002 and [11C]AZ12175002 compared with structurally similar 
[11C]AZ11895987. Conformation a and b refers to open conformations and c refers to the H-bonding 
conformation. 
Conformer 
Enthalpy 
Gibbs free 
energy Dipole moment 
(Debye) (ΔH) (ΔG) 
(kcal/mol) (kcal/mol) 
AR-A000002a 0 0 29.4 
AR-A000002b −1.7 1.1 12.1 
AR-A000002c 0.1 2.6 14.1 
AZ12175002a 0 0 25.4 
AZ12175002b 1.3 2.2 17.0 
AZ12175002c −1.6 0.2 12.5 
AZ11895987a 0 0 30.9 
AZ11895987b −0.2 1.8 14.4 
AZ11895987c −1.8 0.2 12.6 
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5 SUMMARY OF FINDINGS 
 
The overall focus within this thesis has been to develop 5-HT1B PET radioligands to image 5-
HT1B receptors in brain. In total three novel carbon-11 PET radioligands were developed, 
[11C]AZ10419096, [11C]AZ11136118, [11C]AZ11895987; one carbon-11 PET radioligand 
which previously had been published was further investigated, [11C]AZ12175002; and one 
fluorine-18 PET radioligand was developed, [18F]AZ10419096 (Figure 14). 
 
[11C]AZ10419096 [11C]AZ11895987 [11C]AZ11136118 [11C]AZ12175002 [18F]AZ10419096 
paper I & III paper II paper II paper III paper IV 
Figure 14. The 5-HT1B PET radioligands that have been developed as part of this thesis. 
In paper I, [11C]AZ10419096: a full antagonist 5-HT1B PET radioligand labelled with carbon-
11 was developed. [11C]AZ10419096 showed high specific binding in pretreatment PET 
measurements and was displaced by fenfluramine-induced increase in 5-HT concentrations in 
a dose-dependent manner. 
In paper II, no full agonist PET radioligand was developed. Two full agonists were identified 
but neither was useful as a PET radioligand. The high-affinity agonists were labelled with 
carbon-11 and both showed poor brain uptake and no specific binding could be detected in PET 
measurements. No clear reason could be determined for the poor performance of the agonist 
PET radioligands.  
In paper III, a highly agonistic, previously published compound was further developed and 
characterized, [11C]AZ12175002, and could be used in an initial pilot study comparing three 
PET radioligands, [11C]AZ10419096, [11C]AZ10419369 and [11C]AZ12175002, with differing 
intrinsic activity. Displacement PET measurements comparing two different doses of 
fenfluramine were performed and resulted in useful guidelines for a future larger study in 
imaging the different affinity states of the 5-HT1B receptor. 
In paper IV, a fluorine-18 labelled 5-HT1B PET radioligand, [
18F]AZ10419096, that is the 
identical structure of [11C]AZ10419096 was developed and showed high specific binding in 
pretreatment PET measurements. This is the first promising fluorine-18 labelled 5-HT1B PET 
radioligand but will require further development before it can be used in any larger PET study.  
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6 FUTURE CONSIDERATIONS AND CHALLENGES 
 
Development of agonist CNS PET radioligands.  The disappointing results in developing a 
full agonist 5-HT1B PET radioligand does not mean it is impossible to do so. Future projects 
with this aim will need to find new candidate compounds, which would mean setting up in vitro 
assays to determine affinity and efficacy. The candidate compounds could be structurally 
similar to the failed agonists developed herein and one idea would be to reverse the amide bond 
of the two full agonist tested, [11C]AZ11136118 and [11C]AZ11895987, or incorporate a 
hetero-atom in the bicyclic ring.  
A pretreatment PET measurement using either [11C]AZ11136118 or [11C]AZ11895987 with a 
SSRI as blocking agent would answer the speculation of whether 5-HTT transportation of the 
radioligands is the reason for the poor binding and poor brain uptake for both full agonists. 
Intrinsic activity evaluation. A complete study into agonist/antagonist relative ability to 
measure changes in endogenous 5-HT concentration could be performed. A recommendation 
for how such a study should be designed was outlined in paper III. Three PET radioligand with 
differing intrinsic activity were identified with dose dependent displacement by fenfluramine-
induced changes in endogenous 5-HT concentrations.  
[18F]AZ10419096. The first fluorine-18 labelled PET radioligand for imaging 5-HT1B 
receptors in brain show good characteristics for further development. Some issues remain to be 
resolved before that can take place. 
A reliable synthesis route for the precursor needs to be established, subsequent attempts at 
precursor synthesis by an external contractors has failed. If a reliable synthesis route cannot be 
established for this precursor, a different overall approach needs to be developed using different 
precursor and different radiofluorination methodology. A precursor for radiofluorination on the 
other fluorine-site of the AZ10419096 molecule would be the obvious first option (Figure 7). 
If the boronic ester precursor to [18F]AZ10419096 can be reliably synthesized, optimization to 
the radiofluorination would be needed. Reducing the amount of precursor needed per synthesis 
is key for further development. Developing the existing radiofluorination methodology on a 
micro-fluidic system could reduce the amount of precursor and solvent in the reaction mixture 
while maintaining the stoichiometric ratios.
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